Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06569459 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer

Name: Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer — clinical trial record (NCT06569459)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusUnknown

PhasePhase 2

SponsorThe First Affiliated Hospital with Nanjing Medical University

Started2024-07-09

View on ClinicalTrials.gov ↗

Record status

This record was last updated August 26, 2024 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2026-09-06

Trial status changed: Recruiting → Unknown

The First Affiliated Hospital with Nanjing Medical University

275 trials monitored

See 6 trials at risk

Esophageal Cancer

1,010 trials monitored

See 51 trials at risk

This study is a double-arm, randomized, controlled, single-center, phase II clinical trial aimed at evaluating the efficacy and safety of chemoradiotherapy plus immunotherapy with or without Trilaciclib in the treatment of locally advanced esophageal squamous cell carcinoma that is not resectable.

Trial Details

NCT Number	NCT06569459
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University
Conditions	Esophageal Cancer
Enrollment	60 participants
Start Date	2024-07-09
Primary Completion	2025-11-30 (estimated)
Study Completion	2026-07-31 (estimated)
Updated on ClinicalTrials.gov	2024-08-26